KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Sarepta Therapeutics (SRPT) over the last 9 years, with Q2 2025 value amounting to $152.6 million.

  • Sarepta Therapeutics' Cost of Revenue rose 24248.06% to $152.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $421.1 million, marking a year-over-year increase of 13884.5%. This contributed to the annual value of $319.1 million for FY2024, which is 11224.73% up from last year.
  • Per Sarepta Therapeutics' latest filing, its Cost of Revenue stood at $152.6 million for Q2 2025, which was up 24248.06% from $132.3 million recorded in Q4 2024.
  • Sarepta Therapeutics' Cost of Revenue's 5-year high stood at $152.6 million during Q2 2025, with a 5-year trough of $19.5 million in Q2 2021.
  • For the 5-year period, Sarepta Therapeutics' Cost of Revenue averaged around $50.5 million, with its median value being $37.0 million (2023).
  • In the last 5 years, Sarepta Therapeutics' Cost of Revenue plummeted by 971.29% in 2023 and then skyrocketed by 24248.06% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' Cost of Revenue (Quarter) stood at $31.7 million in 2021, then fell by 2.98% to $30.8 million in 2022, then surged by 43.43% to $44.2 million in 2023, then surged by 199.49% to $132.3 million in 2024, then increased by 15.31% to $152.6 million in 2025.
  • Its last three reported values are $152.6 million in Q2 2025, $132.3 million for Q4 2024, and $91.7 million during Q3 2024.